



Press Release

**MEDIAN broadens its client base  
with the award of a new €2.2M project  
for image management in a phase III study**

- ✓ Project awarded for the management of medical images in a Phase III study for non-small cell lung cancer;
- ✓ The project is sponsored by a European biopharmaceutical company.

**Sophia Antipolis, France – November 3, 2014** – MEDIAN Technologies (ALMDT.PA), a leading medical imaging solutions and service provider for image interpretation and management in oncology clinical trials, cancer screening programs and routine practice in oncology, announced today that it has been selected to provide imaging solutions and services for a new Phase III study, conducted by a European biopharmaceutical company.

The project awarded [\*] to MEDIAN pertains to a clinical trial on non-small cell lung cancer, and will represent approximately €2.2M for MEDIAN

*"We are extremely proud of this new project award. This being another new phase III project awarded to MEDIAN Technologies in 2014, it validates our economic development model, moving naturally from Phase II to Phase III image management studies. This was one of our initial assumptions for the company organic growth; it is proven out again today," said Jerome Windsor, VP of Pharma Business Development.*

With this project, scheduled to start before the end of 2014, MEDIAN also broadens its client base.

*[\*] A project award notifies a company that their solution has been selected for a given project. This should result in a firm contract within 18 months, subject to the confirmation of clinical results during the first phase.*

**ALMDT**  
**LISTED**  
**NYSE**  
**ALTERNEXT**

**About MEDIAN Technologies:** MEDIAN Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. MEDIAN Technologies standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. MEDIAN serves two primary markets: drug development and patient care. MEDIAN has a strategic partnership with the world's largest CRO (Contract Research Organization) to offer integrated imaging services for clinical trials to biopharma sponsors worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market.



Founded in 2002, MEDIAN Technologies is based in Sophia-Antipolis, France, and has a US subsidiary in Boston. MEDIAN has a global reach and actively works with clinical sites located in Asia, Europe, North and South America, and Australia. MEDIAN has received the label "Innovative Company" by the BPI and is listed on Euronext Paris' Alternext market. (ISIN: FR0011049824, ticker: ALMDT). The company is eligible for the PEA PME SME equity savings plan setup. For more information on MEDIAN, please visit: [www.mediantechologies.com](http://www.mediantechologies.com)

*"We are committed to the improvement of cancer patient outcomes through innovation in medical imaging and quality execution for better screening, diagnosis, and monitoring of patients."*



## Contacts

<b>MEDIAN Technologies</b> Fredrik Brag, CEO +33 4 92 90 65 82 <a href="mailto:fredrik.brag@mediantechnologies.com">fredrik.brag@mediantechnologies.com</a>	<b>Press</b> <b>ALIZE RP</b> Caroline Carmagnol Sophie Colin + 33 1 70 22 53 93 <a href="mailto:median@alizerp.com">median@alizerp.com</a>	<b>Investors</b> <b>ACTIFIN</b> Ghislaine Gasparetto <a href="mailto:ggasparetto@actifin.fr">ggasparetto@actifin.fr</a> +33 1 56 88 11 11
--	---	---